Preclinical screening methods in cancer

Area of Science:

• Oncology
• Pharmacology
• Drug Discovery

Background:

• Cancer is a leading global cause of death, characterized by uncontrolled cell growth.
• A significant majority of anticancer drugs fail in clinical trials, often due to preclinical limitations.
• Current preclinical screening methods have inherent advantages and disadvantages.

Purpose of the Study:

• To provide an overview of preclinical methods used in anticancer drug screening.
• To analyze the pros and cons of various *in vitro* and *in vivo* models.
• To emphasize the importance of selecting appropriate models to improve drug development success rates.

Main Methods:

• Review of established preclinical cancer models.
• Comparative analysis of *in vitro* human cancer cell lines.
• Evaluation of *in vivo* tumor xenograft and genetically engineered mouse models.

Main Results:

• Each preclinical model possesses unique strengths and weaknesses.
• Model selection significantly impacts the predictive value for clinical efficacy.
• Diverse mechanisms of action require tailored preclinical approaches.

Conclusions:

• Optimizing preclinical anticancer drug screening is essential to reduce high attrition rates.
• Careful selection and application of preclinical models can enhance the success of anticancer compounds in clinical trials.
• This review aids researchers in choosing appropriate methods for effective anticancer drug development.